欢迎您！东篱公司
退出
-
申报数据库
-
立项数据库
-
成果数据库
-
项目获奖数据库
中文摘要：
糖尿病是以胰岛素相对或绝对不足为特征的代谢性疾病，严重危害人类健康，传统抗糖尿病药物各有缺点，从而催生了抗糖尿病肽类药物的面世。常见于文献报道的抗糖尿病肽有胰高血糖素样肽-1（Glucagon-likepeptide-1，GLP-1）受体激动剂、基于胰淀素开发的抗糖尿病肽、动植物来源的抗糖尿病肽和抗糖尿病寡肽，其中前者又包括GLP-1衍生物和GLP-1类似物。该文对它们各自的优缺点，研发思路和药理效应作了综述。
英文摘要：
Diabetes Mellitus （DM） is a metabolic syndrome characterized by absolutely or comparatively insufficient insulin. DM is substantially hazardous to human health. The defects of traditional antihyperglycemic drugs have accelerated the development of peptide-based antidiabetic agents. Such agents frequently reported in published works are Glucagon-like peptide-1 （ GLP-1 ） receptor agonists that include GLP-1 derivatives and GLP-1 analogs, amylin-based antidiabetic peptides （ABAPs） , animals or plants-derived antidiabetic peptides （APDAPs） and antidiabetic oligopeptides （ADOPs）. This review summarizes the existing knowledge concerning advantages, drawbacks, developing thoughts and pharmaceutical effects of the four kinds of pcptides, respectively.
同期刊论文项目
同项目期刊论文
期刊信息
位置：